You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 146 No. 2, February 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Failure of Thrombolytic Therapy in Four Children With Extensive Thromboses

C. Anthony Ryan, MB, MRCPI, MRCP(UK), FRCPC; Maureen Andrew, MD, FRCPC

Am J Dis Child. 1992;146(2):187-193.


Abstract

• In three children with central vein thromboses and a fourth with a pulmonary artery thrombosis, thrombolytic therapy failed to produce ultrasonographic evidence of clot lysis. Low-dose streptokinase (50 to 250 U/kg per hour) was infused directly into the clot in three children, followed by streptokinase and urokinase in systemic doses (streptokinase, 1000 to 1750 U/kg per hour; urokinase, 4400 to 5000 U/kg per hour). A fourth child treated sequentially with systemic doses of streptokinase, urokinase, and recombinant tissue-type plasminogen activator developed a significant retroperitoneal and intrapleural hemorrhage after 19 hours of recombinant tissue-type plasminogen activator infusion at a dose of 0.7 mg/kg per hour. All of the children survived. The most likely reason for treatment failure was that the clots (estimated to be between 2 and 3 weeks of age) were organized and thus resistant to lysis. Early diagnosis and prompt thrombolysis of significant lesions may contribute to the successful management of pediatric thrombosis. However, controlled studies are clearly needed to establish guidelines for the optimal use of thrombolytic agents in children.

(AJDC. 1992;146:187-193)



Author Affiliations

From the Pediatric Intensive Care Unit, Department of Pediatrics, University of Alberta Hospitals, Edmonton (Dr Ryan); and Department of Pediatrics, McMaster University Medical Center, Hamilton, Ontario (Dr Andrew).


Footnotes

Accepted for publication September 16, 1991.

Reprint requests to 2C300 Walter Mackenzie Health Sciences Centre, University of Alberta Hospitals, Edmonton, Alberta, Canada T6G 2R7 (Dr Ryan).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Monagle et al.
Chest 2008;133:887S-968S.
ABSTRACT | FULL TEXT  

Thrombolysis in Neonates
Collin
CLIN PEDIATR 2001;40:109-110.
 

High-Dose Urokinase Therapy in Newborn Infants with Major Vessel Thrombosis
Giacoia
CLIN PEDIATR 1993;32:231-237.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.